Welcome!

News Feed Item

BD Announces Results For 2014 First Fiscal Quarter

-- Raises the bottom end of full fiscal year 2014 revenue and earnings ranges for guidance.

FRANKLIN LAKES, N.J., Feb. 4, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.0 billion for the first fiscal quarter ended December 31, 2013, representing an increase of 6.0 percent from the prior-year period, or 6.7 percent on a foreign currency-neutral basis. Revenue growth was aided, in part, by favorable timing of orders in the BD Medical and BD Diagnostics segments.

"Fiscal year 2014 is off to a strong start," said Vincent A. Forlenza, Chairman, CEO and President. "Our revenue and earnings growth exceeded our expectations and we have continuing confidence that we have built a solid foundation for future growth. Accordingly, we are raising the bottom end of our previous revenue and earnings ranges for our full fiscal year guidance."

First Quarter Earnings
Reported diluted earnings per share from continuing operations for the first quarter were $1.37 compared with $1.35 in the prior-year period, representing a 1.5 percent increase. On a foreign currency-neutral basis, diluted earnings per share from continuing operations for the first quarter increased by 8.1 percent. Adjusted diluted earnings per share from continuing operations excluding the medical device excise tax, which went into effect in January 2013 under the U.S. healthcare reform law, were $1.42, or an increase of 11.9 percent.

Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $1.06 billion, representing an increase of 8.2 percent compared with the prior-year period, or an increase of 8.6 percent on a foreign currency-neutral basis. The segment's revenue growth reflects strong sales in the Medical Surgical Systems and Diabetes Care units and solid sales in the Pharmaceutical Systems unit. Both the Medical Surgical and Pharmaceutical Systems units also benefitted from favorable timing of orders.

In the BD Diagnostics segment, worldwide revenues for the quarter were $672 million, representing an increase of 3.1 percent compared with the prior-year period, or 4.2 percent on a foreign currency-neutral basis. The segment's growth was driven by international expansion in both the Preanalytical Systems and Diagnostic Systems business units. Diagnostic systems growth was also aided, in part, from a timing of flu orders.

In the BD Biosciences segment, worldwide revenues for the quarter were $279 million, representing an increase of 5.4 percent compared with the prior-year period, or an increase of 5.7 percent on a foreign currency-neutral basis. The segment's growth was driven by continued strength in emerging markets, clinical reagents sales and solid instrument placements in both the U.S. and Western Europe.

Geographic Results
First quarter revenues in the U.S. of $849 million represent an increase of 2.3 percent over the prior-year period. Revenues outside of the U.S. were $1.17 billion, representing an increase of 8.9 percent compared with the prior-year period, or an increase of 10.0 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and sales of safety-engineered products in addition to solid growth in Western Europe.

Fiscal 2014 Outlook for Full Year
The Company estimates that reported and currency-neutral revenues for the full fiscal year 2014 will increase 4.5 to 5.0 percent. The Company expects reported diluted earnings per share from continuing operations for the full fiscal year 2014 to be between $6.19 and $6.22, which represents growth of 6.5 to 7.0 percent over 2013 adjusted diluted earnings per share of $5.81.  On a foreign currency-neutral basis, adjusted diluted earnings per share are expected to grow about 9.0 to 9.5 percent, or 9.5 to 10.0 percent excluding the incremental impact of the medical device tax.  The Company plans to repurchase, subject to market conditions, about $450 million of its common stock in fiscal year 2014.

Conference Call Information
A conference call regarding BD's first quarter results will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Tuesday, February 4th, 2014.  The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Tuesday, February 11, 2014, confirmation number 31318159.

Non-GAAP Financial Measures/Financial Tables
This news release contains certain non-GAAP financial measures.  Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.  Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers.  Percentages and earnings per share amounts presented are calculated from the underlying whole-dollar amounts.

About BD
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2014 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement.  These factors include, but are not limited to: potential cuts in healthcare spending by the U.S. government as part of deficit reduction measures which could result in reduced demand for our product or downward pricing pressure; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; the adverse impact of cyber-attacks on our information systems; competitive factors; pricing and market pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission.  We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contact:
Monique N. Dolecki, Investor Relations – 201-847-5453
Alyssa J. Zeff, Corporate Communications – 201-847-4358

 

BECTON DICKINSON AND COMPANY


CONSOLIDATED INCOME STATEMENTS


(Unaudited; Amounts in millions, except share and per share data)











Three Months Ended December 31,



2013


2012


% Change










REVENUES

$

2,015

$

1,900


6.0










Cost of products sold


980


894


9.6


Selling and administrative 


531


496


7.1


Research and development


126


118


6.4


TOTAL OPERATING COSTS








     AND EXPENSES


1,637


1,508


8.5










OPERATING INCOME


378


392


(3.6)










Interest income


14


8


75.7


Interest expense


(34)


(35)


(4.3)


Other income, net


1


1


(14.0)










INCOME FROM CONTINUING OPERATIONS BEFORE








     INCOME TAXES


359


366


(1.9)










Income tax provision


88


95


(8.3)










INCOME FROM CONTINUING OPERATIONS


271


270


0.4










INCOME FROM DISCONTINUED OPERATIONS








   NET OF INCOME TAX PROVISION OF








   $0 AND $216, RESPECTIVELY


-


355


        NM 










NET INCOME

$

271

$

625


(56.6)










EARNINGS PER SHARE
















Basic:








Income from continuing operations

$

1.40

$

1.38


1.4


Income from discontinued operations

$

-

$

1.81


        NM 


Net income 

$

1.40

$

3.18


(56.0)










Diluted:








Income from continuing operations

$

1.37

$

1.35


1.5


Income from discontinued operations

$

-

$

1.78


        NM 


Net income 

$

1.37

$

3.13


(56.2)


















AVERAGE SHARES OUTSTANDING (in thousands)
















     Basic


194,203


196,427




     Diluted


198,110


199,570












NM - Not Meaningful








 

BECTON DICKINSON AND COMPANY


SUPPLEMENTAL REVENUE INFORMATION


REVENUES BY SEGMENT AND GEOGRAPHIC AREA


(Unaudited; Amounts in millions)











Three Months Ended December 31,



2013


2012


% Change










BD MEDICAL








   United States

$

441

$

425


3.8


   International


622


558


11.5


TOTAL

$

1,064

$

983


8.2










BD DIAGNOSTICS








   United States

$

321

$

321


0.1


   International


351


331


6.0


TOTAL

$

672

$

652


3.1










BD BIOSCIENCES








   United States

$

87

$

84


3.3


   International


192


181


6.3


TOTAL

$

279

$

265


5.4










TOTAL REVENUES








   United States

$

849

$

830


2.3


   International


1,166


1,070


8.9


TOTAL

$

2,015

$

1,900


6.0


 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended December 31,

(Unaudited; Amounts in millions)









United States



2013


2012


 % Change 








BD MEDICAL







   Medical Surgical Systems

$

262

$

249


5.3

   Diabetes Care


122


112


8.4

   Pharmaceutical Systems


57


64


(10.4)

TOTAL

$

441

$

425


3.8








BD DIAGNOSTICS







   Preanalytical Systems

$

171

$

167


2.7

   Diagnostic Systems


149


154


(2.7)

TOTAL

$

321

$

321


0.1








BD BIOSCIENCES

$

87

$

84


3.3








TOTAL UNITED STATES

$

849

$

830


2.3

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended December 31, (continued)

(Unaudited; Amounts in millions)













International







 % Change 



2013


2012


 Reported 


FXN


FX Impact












BD MEDICAL











   Medical Surgical Systems

$

317

$

287


10.4


12.4


(2.0)

   Diabetes Care


142


130


8.7


11.5


(2.8)

   Pharmaceutical Systems


164


141


16.4


12.6


3.8

TOTAL

$

622

$

558


11.5


12.2


(0.7)












BD DIAGNOSTICS











   Preanalytical Systems

$

176

$

168


4.8


6.1


(1.3)

   Diagnostic Systems


175


164


7.2


10.2


(3.0)

TOTAL

$

351

$

331


6.0


8.1


(2.1)












BD BIOSCIENCES

$

192

$

181


6.3


6.8


(0.5)












TOTAL INTERNATIONAL

$

1,166

$

1,070


8.9


10.0


(1.1)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended December 31, (continued)

(Unaudited; Amounts in millions)













Total







 % Change 



2013


2012


 Reported 


FXN


FX Impact












BD MEDICAL 











   Medical Surgical Systems

$

579

$

536


8.0


9.1


(1.1)

   Diabetes Care


264


243


8.6


10.1


(1.5)

   Pharmaceutical Systems


221


205


8.0


5.5


2.5

TOTAL

$

1,064

$

983


8.2


8.6


(0.4)












BD DIAGNOSTICS











   Preanalytical Systems

$

347

$

335


3.7


4.4


(0.7)

   Diagnostic Systems


325


317


2.4


3.9


(1.5)

TOTAL

$

672

$

652


3.1


4.2


(1.1)












BD BIOSCIENCES

$

279

$

265


5.4


5.7


(0.3)












TOTAL REVENUES

$

2,015

$

1,900


6.0


6.7


(0.7)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

SAFETY REVENUES

(Unaudited; Amounts in millions)













Three Months Ended December 31,







 % Change 



2013


2012


 Reported 


FXN


FX Impact












TOTAL SAFETY REVENUES











   United States

$

315

$

291


8.1


8.1


-

   International


242


220


10.1


12.0


(1.9)

TOTAL

$

557

$

511


9.0


9.8


(0.8)












BY SEGMENT











   BD Medical

$

285

$

252


13.0


14.0


(1.0)

   BD Diagnostics


272


259


5.0


5.7


(0.7)

TOTAL

$

557

$

511


9.0


9.8


(0.8)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2014 Quarter-to-Date Reconciliation of Non-GAAP Financial Measures

(Unaudited)

















Three Months Ended December 31,



2013


2012


Growth


Foreign Currency Translation


Foreign Currency Neutral Change


Growth %


Foreign Currency Neutral Growth %
















Reported Diluted Earnings per Share from Continuing Operations

$

1.37

$

1.35

$

0.02

$

(0.09)

$

0.11


1.5%


8.1%
















Medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act
($14 million or $9 million after-tax)


0.05


0.00


























Adjusted Diluted Earnings per Share from Continuing Operations without Medical Device Excise Tax

$

1.42

$

1.35

$

0.07

$

(0.09)

$

0.16


5.2%


11.9%

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2014 Outlook Reconciliation










Reported







Basis


FX Impact


FXN Basis








Revenues - Full Year 2014 estimated growth


4.5% - 5.0%


0.0%


4.5% - 5.0%













































Full Year


Full Year





2014


2013


% Increase



(estimated)





Reported Fully Diluted Earnings per Share 







from Continuing Operations

$

6.19 - 6.22

$

4.67


NM








Pending Litigation Settlement (1)




0.07










Verdict Charge (2)




1.06










Pension Settlement Charge (3)




0.02










Adjusted Fully Diluted Earnings per Share 







from Continuing Operations

$

6.19 - 6.22

$

5.81


6.5% - 7.0%








FX Impact






(2.5%)








Adjusted FXN Growth






9.0% - 9.5%








Medical Device Excise Tax Impact (4)






(0.5%)








Adjusted FXN Growth (excluding the medical device excise tax)






9.5% - 10.0%

 

(1) Charge associated with the pending litigation settlement related to indirect purchaser antitrust class action cases.












(2) Charge associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit filed against the Company by RTI.












(3) Represents a non-cash pension settlement charge associated with lump sum benefit payments made from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost for the year. The charge also included settlement losses associated with certain foreign pension plans.












(4) Represents the incremental impact of the medical device excise tax in first quarter fiscal year 2014 (tax went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act).























NM - Not Meaningful











FXN = Foreign Currency Neutral











 

SOURCE BD (Becton, Dickinson and Company)

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
The IoT has the potential to create a renaissance of manufacturing in the US and elsewhere. In his session at 18th Cloud Expo, Florent Solt, CTO and chief architect of Netvibes, will discuss how the expected exponential increase in the amount of data that will be processed, transported, stored, and accessed means there will be a huge demand for smart technologies to deliver it. Florent Solt is the CTO and chief architect of Netvibes. Prior to joining Netvibes in 2007, he co-founded Rift Technol...
Struggling to keep up with increasing application demand? Learn how Platform as a Service (PaaS) can streamline application development processes and make resource management easy.
If there is anything we have learned by now, is that every business paves their own unique path for releasing software- every pipeline, implementation and practices are a bit different, and DevOps comes in all shapes and sizes. Software delivery practices are often comprised of set of several complementing (or even competing) methodologies – such as leveraging Agile, DevOps and even a mix of ITIL, to create the combination that’s most suitable for your organization and that maximize your busines...
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...
See storage differently! Storage performance problems have only gotten worse and harder to solve as applications have become largely virtualized and moved to a cloud-based infrastructure. Storage performance in a virtualized environment is not just about IOPS, it is about how well that potential performance is guaranteed to individual VMs for these apps as the number of VMs keep going up real time. In his session at 18th Cloud Expo, Dhiraj Sehgal, in product and marketing at Tintri, will discu...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
SYS-CON Events announced today that Enzu, a leading provider of cloud hosting solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to foc...
SYS-CON Events announced today that Stratoscale, the software company developing the next generation data center operating system, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Stratoscale is revolutionizing the data center with a zero-to-cloud-in-minutes solution. With Stratoscale’s hardware-agnostic, Software Defined Data Center (SDDC) solution to store everything, run anything and scale everywhere...
Digital payments using wearable devices such as smart watches, fitness trackers, and payment wristbands are an increasing area of focus for industry participants, and consumer acceptance from early trials and deployments has encouraged some of the biggest names in technology and banking to continue their push to drive growth in this nascent market. Wearable payment systems may utilize near field communication (NFC), radio frequency identification (RFID), or quick response (QR) codes and barcodes...
Angular 2 is a complete re-write of the popular framework AngularJS. Programming in Angular 2 is greatly simplified – now it's a component-based well-performing framework. This immersive one-day workshop at 18th Cloud Expo, led by Yakov Fain, a Java Champion and a co-founder of the IT consultancy Farata Systems and the product company SuranceBay, will provide you with everything you wanted to know about Angular 2.
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...